Physician profile
Ortal Babaev
NPI 1467074153
$1,274.16
in general payments reported to CMS, 2019-2025
17 companies · $635 in 2025
The $635 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $177 · 2024: $462 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $221.62 | 2024-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $146.35 | 2024-2025 | |
| Exact Sciences Corporation | $130.21 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $126.24 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Viiv Healthcare Company | $102.14 | 2025 | Apretude |
| Sumitomo Pharma America, INC. | $84.04 | 2024-2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $72.08 | 2023-2025 | Zoryve, Seglentis |
| Boston Scientific Corporation | $56.43 | 2025 | Watchman Flx |
| Irhythm Technologies, INC. | $55.32 | 2023 | Zio Xt Patch |
| Glaxosmithkline, LLC. | $54.18 | 2024-2025 | Arexvy, Shingrix |
| Philips North America LLC | $49.52 | 2025 | Diagnostic Ecg Service |
| Astrazeneca Pharmaceuticals Lp | $47.87 | 2024-2025 | Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.46 | 2023 | Lifevest |
| Phadia US INC. | $29.56 | 2025 | Immunocap |
| Phathom Pharmaceuticals, INC. | $23.49 | 2024-2025 | Voquezna |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $22.95 | 2024 | |
| Merck Sharp & Dohme LLC | $21.70 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ortal Babaev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.